Published in Blood Weekly, July 8th, 2004
The data demonstrated positive trends in both patient response and safety. NeoRx is developing STR for use with high-dose chemotherapy and stem-cell transplantation. The company recently initiated a phase III pivotal study of STR in multiple myeloma, a cancer that arises in the bone marrow.
Of the 10 evaluable patients treated in the dosimetry study, 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.